News Release
![]() |
<< Back |
![]() |
Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors
|
Former Head of Global Government Affairs and Policy at
“With more than 30 years of experience in the biopharma and healthcare
industry, Dr. Gollaher is an outstanding addition to our Board,” said
“I’m honored to join Cidara’s board of directors at an exciting moment
as the company moves into late-stage clinical development,” said
Dr. Gollaher served as vice president of worldwide government affairs
and policy for
Additionally, in June of 2018, Dr. Gollaher was appointed a Senior
Fellow at the
About
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate,
formerly known as CD101 IV, through clinical trials. Rezafungin has
improved pharmacokinetics compared to existing echinocandins and the
potential for expanded utility across patient settings. It is the only
once-weekly product candidate in development for the treatment and
prevention of life-threatening invasive fungal infections. The company’s
Phase 2 STRIVE clinical trial of rezafungin met its primary safety and
efficacy objectives, and provides support for Cidara to initiate Phase 3
pivotal trials in the treatment of candidemia and invasive candidiasis
and the prophylaxis of invasive fungal infections. Cidara also is
leveraging its novel Cloudbreak™ platform to develop antibody-drug
conjugates for the treatment of multi-drug resistant Gram-negative
bacterial infections. Cloudbreak is the first immunotherapy discovery
platform designed specifically to create compounds that directly kill
pathogens and also direct a patient’s immune cells to attack and
eliminate bacterial, fungal or viral pathogens. Cidara is headquartered
in
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, the impact of Dr. Gollaher’s appointment to Cidara’s board of
directors and our ability to advance our pipeline to deliver novel
anti-infectives to patients and providers, the potential for the
expanded utility of rezafungin across patient settings, and Cidara’s
ability to successfully complete development of rezafungin and receive
regulatory approval for any indication. Risks that contribute to the
uncertain nature of the forward-looking statements include: the success
and timing of Cidara’s preclinical studies and clinical trials;
regulatory developments in
View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005164/en/
Source:
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl
Managing
Director
858-356-5932
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran
615-414-8668
ChristyCurran@sambrown.com